Written by Amanda Mathews
Spoon Feed
This paper summarizes three professional society recommendations for management of atrial fibrillation in the ED, including rate and rhythm control and when to anticoagulate.
Afib recap
This paper compared the clinical guidelines for the management of atrial fibrillation (AF) in the ED from the European Society of Cardiology, American College of Cardiology/American Heart Association, and Canadian Cardiovascular Society/Canadian Heart Rhythm Society. Of note, only the Canadian Society had EM physician representation on the committee. Here are the key takeaways in four categories.
Prevention of Stroke and Systemic Embolism
- Use a validated risk tool endorsed by your country’s guidelines (CHA2DS2-VASc) to determine who should be anticoagulated.
- DOACs are the first line for AF patients, with warfarin only for patients with mechanical valves or moderate-severe mitral stenosis.
- Aspirin is not recommended for prevention of stroke and systemic embolism.
Rhythm Control in the ED
- A patient with AF/flutter and hemodynamic instability thought to be attributable to AF/flutter should receive urgent electrical cardioversion, regardless of whether they have had pretreatment with 3 or more weeks of anticoagulation.
- Guidelines support cardioversion of stable patients with nonvalvular AF for <48 hours who have also not been on anticoagulation for 3 or more weeks prior to presentation.
- The American guidelines are not firm on whether or not patients require 4 weeks of anticoagulation after successful cardioversion. If already on AC, it can be continued; but for patients who are low-risk by CHA2DS2-VASc, or for AF for less than 12 hours, the benefit of AC is uncertain.
- Pharmacological cardioversion can be used in the absence of preexcitation in patients who do not have other contraindications. Amiodarone is safest for patients with HFrEF.
Rate Control in the ED
- Target resting HR is up to 110.
- Beta blockers and nondihydropyridine calcium channel blockers remain first-line therapy for hemodynamically stable patients with a normal ejection fraction, with digoxin as a second-line agent.
- In patients with decompensated heart failure or hypotension, use intravenous digoxin or amiodarone.
Post ED Referrals
- New AF should be referred to an electrophysiologist and follow-up with PCP within one week.
- If the patient qualifies for anticoagulation, write a prescription for 14–30 days.
How will this change my practice?
Ultimately, this paper reinforces many standard practices in the treatment of AF in emergency medicine. It’s a good refresher on professional society recommendations to make sure you and your organization are operating within the standard of care.
Source
Comparing Guidelines for Atrial Fibrillation: Focus on Emergency Medicine. Ann Emerg Med. 2026 Jan 27:S0196-0644(25)01291-0. doi: 10.1016/j.annemergmed.2025.10.004. Epub ahead of print. PMID: 41603838.
I thought the latest recommendations was that if less than 12 hours and chadvasc was less than 2 then safe to cardiovert but the risk of cardioversion goes up after the 12 hour mark as an independent risk factor.
It depends on hemodynamic stability. If unstable, DCCV is the right approach. If stable, decisions are more nuanced.
sure I understand that. What I am questioning is the 12-48 hr rule. I thought the new guidelines (class 2b) to use DCCV, without prior transesophageal echo to rule out thrombus, in patients with CHA2DS2-VASc score 0-1 and symptom duration <12 hours. After 12 hours but before 48 hours are you cardioverting CHA2DS2-VASc score 0-1 without imaging?